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Abstract: In the last decade, iron and magnesium, both pure and alloyed, have been extensively
studied as potential biodegradable metals for medical applications. However, broad experience
with these material systems has uncovered critical limitations in terms of their suitability for clinical
applications. Recently, zinc and zinc-based alloys have been proposed as new additions to the list of
degradable metals and as promising alternatives to magnesium and iron. The main byproduct of
zinc metal corrosion, Zn2+, is highly regulated within physiological systems and plays a critical role
in numerous fundamental cellular processes. Zn2+ released from an implant may suppress harmful
smooth muscle cells and restenosis in arteries, while stimulating beneficial osteogenesis in bone.
An important limitation of pure zinc as a potential biodegradable structural support, however, lies in
its low strength (σUTS ~30 MPa) and plasticity (ε < 0.25%) that are insufficient for most medical device
applications. Developing high strength and ductility zinc with sufficient hardness, while retaining its
biocompatibility, is one of the main goals of metallurgical engineering. This paper will review and
compare the biocompatibility, corrosion behavior and mechanical properties of pure zinc, as well as
currently researched zinc alloys.
Keywords: zinc; zinc alloys; biodegradable; biocompatible; corrosion degradation; mechanical properties
1. Introduction
Over the last 4 decades, innovations in biomaterials and medical technology have attracted
remarkable attention for their potential to improve human life, by replacing and repairing soft and
hard tissues, such as bone, cartilage, blood vessels, or even entire organs [1,2]. During this time, metals
have become widely used as orthopedic implants, cardiovascular interventional devices, and tissue
engineering scaffolds, due to their high strength and toughness compared with polymers and ceramic
materials [3,4]. Traditional metallic biomaterials with high corrosion resistance, such as titanium alloys,
stainless steels, cobalt–chromium alloys and tantalum are generally used as permanent implants
in patients [3–5]. In most applications, however, the function of the implant is temporary and no
longer needed after full recovery of the treated site. Furthermore, the permanent presence of the
implant can lead to chronic deleterious effects. For instance, metal ions can be released from implanted
devices due to defects in the surface oxide film, eventually resulting in implant fracture. In other cases,
a chronic inflammatory response against the implant may undermine the therapeutic function of the
device. In such circumstances, a second operation may be necessary to extract the implant, resulting in
additional injury and expense [1,3,6,7].
Biodegradable metals represent an alternative approach to the traditional paradigm of corrosion
resistant metals [1,8]. Biodegradable metals are expected to corrode gradually and harmlessly in vivo,
maintain mechanical integrity during the critical tissue healing phase, and then dissolve completely
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upon fulfilling their mission [8]. In the last decade, iron and magnesium, both pure and alloyed,
have been extensively studied as potential biodegradable metals for medical applications [8–15].
However, broad experience with these material systems has uncovered critical limitations in terms of
their suitability for clinical applications [5,16–22]. For instance, the corrosion rates for Fe and Fe-based
alloys are generally substantially below clinical needs, producing similar problems as found with
permanent implants [8,16,23,24]. Their corrosion products do not appear to be excreted or metabolized
at a satisfactory rate, but rather accumulate and repel neighboring cells and biological matrices,
rather than allowing cells to integrate around and within the original footprint of the degrading
implant [25]. On the other hand, pure and alloyed Mg exhibits insufficient mechanical strength as well
as excessive corrosion rates, accompanied by hydrogen gas evolution, pH increases, and premature
loss of mechanical integrity [7,26–29].
Recently, zinc and zinc-based alloys were proposed as new additions to the list of degradable
metals and as promising alternatives to magnesium and iron [30–34]. The following are advantageous
characteristics of zinc and its alloys for use in medical applications:
• Similar to magnesium and iron, zinc is an essential trace element in the human body. It is
a component of more than 300 enzymes and an even greater number of other proteins, highlighting
its indispensable role in human health. Optimal nucleic acid and protein metabolism, as well
as cell growth, division, and function, require sufficient availability of zinc [30,35]. From this
perspective, zinc ions released from the implant during the degradation phase could integrate
into the normal metabolic activity of the host without producing systemic toxic side effects [36].
• Zinc exhibits high chemical activity, with an electrode potential (−0.762 V) falling between that of
magnesium (−2.372 V) and iron (−0.444 V) [36–38]. Pure zinc metal, therefore, exhibits moderate
degradation rates (faster than the slowly degrading Fe and its alloys, but slower than the rapidly
degrading Mg and its alloys) due to passive layers of moderate stability, formed by corrosion
products [19,39–41].
• Zinc and zinc-based alloys are easier to cast and process due to their low melting points,
low chemical reactivity and good machinability [37,42,43]. For instance, unlike Mg based alloys,
the melting of zinc alloys can more conveniently be performed in air [37].
An important limitation of pure zinc as a potential biodegradable structural support, lies in
its low strength (σUTS ~30 MPa) and plasticity (ε < 0.25%) characteristics that are insufficient for
most medical applications [42,44,45]. Developing zinc with high strength and sufficient hardness is
one of the main goals of metallurgical engineering, to broaden its utility as a biomedical implant.
One of the most powerful tools to improve a metal’s mechanical performance is the addition of
alloying elements to the pure metal matrix [36,44]. Researchers have developed Zn-based alloys
with new and more attractive features, modifying their chemical composition and microstructure,
in order to improve mechanical properties, by principally using solid solution and second-phase
strengthening [45]. Furthermore, improvements in the mechanical properties of pure zinc can be
produced by the thermomechanical refinement of grain size, by extrusion, rolling, etc. [9]. This paper
will review and compare the biocompatibility, corrosion behavior and mechanical properties of
pure zinc as well as currently researched zinc alloys. The various types of zinc alloys, in terms of
compositions and phase constituents, are summarized in Table 1.
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Table 1. Common biomedical zinc alloys.
Family Representive Alloys and AlloyingElements (wt %) Main Phases References
Zn–Mg
Zn–0.15Mg α-Zn, Mg2Zn11 [9]
Zn–0.5Mg α-Zn, Mg2Zn11 [9]
Zn–1Mg, ZnMg1 α-Zn, Mg2Zn11 [9,22,42,46,47]
Zn–1.2Mg α-Zn, Mg2Zn11 [3]
Zn–1.5Mg, ZnMg1.5 α-Zn, Mg2Zn11 [36,42]
Zn–3Mg, ZnMg3 α-Zn, Mg2Zn11 [9,42,48]
Zn–1.5Mg–0.1Ca α-Zn, Mg2Zn11, CaZn13 [36]
Zn–1Mg–0.5Ca α-Zn, Mg2Zn11, CaZn13 [47]
Zn–1Mg–1Ca α-Zn, Mg2Zn11, CaZn13 [44]
Zn–1Mg–0.1Sr Zn, MgZn2, SrZn13 [49]
Zn–1Mg–0.5Sr Zn, MgZn2, SrZn13 [49]
Zn–1.5Mg–0.1Sr α-Zn, Mg2Zn11, SrZn13 [36]
Zn–1Mg–1Sr α-Zn, Mg2Zn11, SrZn13 [44]
Zn–1Mg–0.1Mn Zn, MgZn2 [50]
Zn–1.5Mg–0.1Mn Zn, MgZn2 [50]
Zn–Ca
Zn–1Ca α-Zn, CaZn13 [22]
Zn–1Ca–1Sr α-Zn, CaZn13, SrZn13 [44]
Zn–Sr Zn–1Sr α-Zn, SrZn13 [22]
Zn–Al
Zn–0.5Al Zn, Al [9,51]
Zn–1Al Zn, Al [9,52]
Zn–3Al Zn, Al [52]
Zn–5Al Zn, Al [52]
ZnAl4Cu1 Zn, Al [42]
ZA0.1Mg α-Zn, Mg2(Zn,Al)11 [51]
ZA0.3Mg α-Zn, Mg2(Zn,Al)11 [51]
ZA0.5Mg/Zn-0.5Al-0.5Mg α-Zn, Mg2(Zn,Al)11 [51,53]
Zn–0.5Al–0.5Mg–0.1Bi Zn, Mg2(Zn,Al)11, Mg3Bi2 [53]
Zn–0.5Al–0.5Mg–0.3Bi Zn, Mg2(Zn,Al)11, Mg3Bi2 [53]
Zn–0.5Al–0.5Mg–0.5Bi Zn, Mg2(Zn,Al)11, Mg3Bi2 [53]
3.5–.5Al, 0.75–1.25Cu, 0.03–0.08Mg Zn, Al [31]
3.5–4.3Al, 2.5–3.2Cu, 0.03–0.06Mg Zn, Al [31]
5.6–6Al, 1.2–1.6Cu Zn, Al [31]
Zn–Cu
Zn–1Cu η-Zn, ε-CuZn5 [54]
Zn–2Cu η-Zn, ε-CuZn5 [54]
Zn–3Cu η-Zn, ε-CuZn5 [54,55]
Zn–4Cu η-Zn, ε-CuZn5 [37,54]
Zn–3Cu–0.1Mg Zn, CuZn5, Mg2Zn11 [55]
Zn–3Cu–0.5Mg Zn, CuZn5, Mg2Zn11 [55]
Zn–3Cu–1Mg Zn, CuZn5, Mg2Zn11 [55]
Zn–Li
Zn–2Li Zn, α-LiZn4 [25]
Zn–4Li Zn, α-LiZn4 [25]
Zn–6Li Zn, α-LiZn4 [25]
Zn–Li Zn, α-LiZn4 [56]
Zn–Ag
Zn–2.5Ag η-Zn, ε-AgZn3 [45]
Zn–5Ag η-Zn, ε-AgZn3 [45]
Zn–7Ag η-Zn, ε-AgZn3 [45]
2. Zinc in the Human Body
The essential role of zinc in the human body was discovered in 1961 when Iranian farmers
subsisting on a zinc deficiency diet (unrefined flat bread, potatoes, and milk) were found to suffer
from a group of syndromes, consisting of anemia, hypogonadism, and dwarfism. Since this discovery,
interest in the biochemical and clinical aspects of zinc has increased markedly [57]. Presently, it is well
known that zinc is one of the most abundant nutritionally essential elements in the human body [44].
Zinc is present in all organs, tissues, fluids and body secretions, with 86% of its mass residing in
skeletal muscle and bone, 6% in the skin, 5% in the liver, 1.5% in the brain and the remaining
distributed amongst the other tissues [35,58]. At the cellular level, 30–40% is located in the nucleus,
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50% in the cytoplasm, organelles and specialized vesicles (for digestive enzymes or hormone storage)
and the remaining portion in the cell membrane [35,44]. The human zinc requirement is estimated
at 15 mg/day [8,10,11,37] and due to its high importance, the body has developed sophisticated
mechanisms to remove zinc from dietary constituents and transport it to desired locations. The human
body is able to absorb zinc from the environment, regulate its concentration in body fluids, transport it
safely to all tissues of the body and to the sites where its presence is required, and safely excrete excess
amounts from the body through the kidneys [35].
As a vital element, zinc plays an important role in numerous physiological systems, including
immune, sexual, neurosensory (cognition and vision), and cell development and growth [19,30].
Zinc participates in numerous fundamental biological functions, such as nucleic acid metabolism,
signal transduction, apoptosis regulation, and gene expression [22]. Zinc is a critical component of
enzymes involved in protein synthesis and energy production. More than 1200 proteins are predicted
to contain, bind, or transport Zn2+, for example, zinc-finger proteins [44]. At the cellular level, zinc
maintains the structural integrity of biomembranes and is essential for cell proliferation, differentiation
and signaling [19,59]. Zinc plays an important role in bone formation, mineralization, and preservation
of bone mass and can be found in the bone extracellular matrix, where it is co-deposited with calcium
hydroxyapatite [19,22,60]. Indeed, a zinc decrease in bone matrix correlates with aging and skeletal
disease [22,61].
Table 2 summarizes the systemic symptoms resulting from zinc deficiency or excess.
Zinc deficiency contributes to retarded growth, impaired parturition (dystocia), neuropathy, decreased
food intake, diarrhea, dermatitis, hair loss, bleeding tendencies, hypotension, and hypothermia [44].
Zinc deficiency is generally due to insufficient dietary intake. However, it may also be a consequence
of malabsorption and chronic illnesses, such as diabetes, malignancy, liver disease, and sickle cell
disease [35,57]. On the other hand, excessive amounts of Zn2+ in the body may be detrimental to
vital organs, such as the kidney, liver, spleen, brain, and heart [19]. In addition, a prolonged overdose
of zinc results in copper deficiency, provokes hypocupremia, anemia, leucopenia, and neutropenia,
and impairs the Cu–Zn–superoxide dismutase antioxidant enzyme [30,62].
Table 2. The systemic symptoms resulting from zinc deficiency and excess [35,63,64].
Organ or System Zinc Deficiency Zinc Excess
Brain Decreased nerve conduction, neuropsychiatricand neurosensory disorders, mental lethargy Lethargy, focal neuronal deficits.
Respiratory tract - Respiratory disorder after inhalation of zincsmoke, metal fume fever.
Immune system Impaired immune system function, increasedsusceptibility to pathogens Altered lymphocyte function.
Thymus Thymic atrophy -
Skin Skin lesions, decreased wound healing,acrodermatitis -
Gastrointestinal tract - Nausea/vomiting, epigastric pain, diarrhea.
Reproductive system Infertility, retarded genital development,hypogonadism -
Prostate - Elevated risk of prostate cancer.
3. Corrosion Behavior of Zinc in the Physiological Environment
The degradation model, proposed by Zheng et al. [8], for biodegradable metals in a neutral
physiological environment, generally occurs via cathodic and anodic reactions. Metallic corrosion
produces hydroxides, oxides, and hydrogen gas by-products [65]. In the specific case of zinc,
as presented in Figure 1, the reactions include a number of intermediate species, according to
the following:
Anodic reaction : 2Zn → 2Zn2+ + 4e− (1)
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Cathodic reaction : O2 + 2H2O + 4e− → 4OH− (2)
Zn(OH)2 formation : 2Zn
2+ + 4OH− → 2Zn(OH)2 (3)
ZnO formation : Zn(OH)2 → ZnO + H2O (4)
When exposed to body fluid, zinc is oxidized into metal cations following the anodic reaction
in Equation (1). The generated electrons are consumed by a cathodic reaction, corresponding to the
dissolved oxygen reduction in Equation (2). Zn(OH)2 and ZnO corrosion products are likely to form
on the metal surface, without gas evolution, according to Equations (3) and (4). Hence, gas release is
not expected as a result of zinc corrosion, in contrast to the highly problematic hydrogen gas that is
released as a byproduct of magnesium corrosion [8,30,36,59].
It should be noted that the physiological environment is highly aggressive, particularly due to the
high concentration of chloride ions. These ions destabilize the equilibrium between dissolution and
formation of the corrosion product layer, given that chloride ions are able to convert the surface into
soluble chloride salts as follows:
6Zn(OH)2 + Zn
2+ + 2Cl− → 6Zn(OH)2 · ZnCl2 (5)
4ZnO + 4H2O + Zn2+ + 2Cl− → 4Zn(OH)2 · ZnCl2 (6)
The dissolution of the Zn(OH)2 and ZnO surface film components promotes further dissolution
of the exposed metal. Cycles of cathodic and anodic reactions expose the fresh metal substrate
to the physiological solution, form corrosion products, and convert the product into soluble salts.
With progressive exposure, an irregular particle may be separated from the zinc matrix and enter the
surrounding medium [8,36].
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According to Bowen et al. [59], thin layers of zinc oxide were the only product observed during
early stag s (1.5 and 3 months) on the surface of zinc wir s (99.99% purity) mplanted into r t aorta.
However, as corrosion progressed to 4.5 and 6 months, the c rrosion layer thickened nd contained three
different phases/layers: calcium phosphate, zinc oxide, and zinc carbonate. The calcium phosphate layer
appeared on the ext rior surface without forming a true bulk product. Hence, the calcium phosphate
layer was not thought to play a significant role in zinc biocorrosion. The compact corrosion layer
included the two other phases, zinc oxide, and zinc carbonate, with ZnO appearing in formations
isolated from one another by the zinc carbonate phase. This complex corrosion layer suggests
that corrosion products of zinc in body fluid might be similar to those reported for magnesium.
These ceramic degradation products can accumulate as a function of the local tissue’s physiological
mass transfer rate and therefore may impact tissue healing and remodeling [30,59].
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Another important factor that needs to be considered in the corrosion of zinc is the pH value of
the solution. According to Pourbaix diagram, shown in Figure 2, zinc is present as hydrated Zn2+(aq),
over the entire physiological range of pH values and biological standard reduction potentials (~820 mV
to ~−670 mV). The purple arrow in Figure 2 indicates the range of biologically-important standard
potentials determined at pH 7.4 [66]. As reported by Thomas et al. [67] in their investigation of zinc
corrosion as a function of pH, in the pH range 7 to 10, the lowered cathodic reaction rates reduce overall
zinc corrosion rates, and the surface oxides thermodynamically predicted to form in this pH range do
not form an effective corrosion protection barrier. Hence, zinc metals in physiological environments
with a pH of 7.4 will be dissolved over time, as is required for biodegradable medical implants.
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4. Biocompatibility and Biological Performances of Zinc and Evaluated Zinc Alloys
4.1. Pure Zinc
After implantation, Zn2+ will be released fro the zinc implant to the surrounding extracellular
space and eventually into the bloodstream. Thus, the cellular responses to high extracellular Zn2+
will impact the healing process and biocompatibility with zinc-bearing implants [16]. Furthermore,
the response of the host’s immune system will determine whether the implant becomes biointegrated
and continues to function as designed, or encapsulated in a dense fibrous tissue that may compromise
the intended function of the implant. The inflammatory cells are sensitive to the implant’s corrosion
behavior and cellular accessibility of the surface product, with more porous and actively corroding
interfaces eliciting more benign inflammatory responses, relative to surfaces that are more resistant to
biocorrosion [20,68]. The inflammatory response can therefore potentially be regulated by controlling
implant degradation behavior and rates through alloying and processing.
4.1.1. In Vitro Examination
Törne et al. [32] investigated the initial degradation of zinc exposed to simulated (phosphate
buffered saline (PBS), Ringer’s saline solution) and physiological body fluids (human plasma, whole
blo d). The f t corrosion rate over time when immersed in body fluids and
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an increase when placed in simulated body fluids. The passivation film that formed in physiological
body fluids was uniform and was composed of inorganic corrosion products and organic materials
(biomolecules). In contrast, the simulated body fluids promoted localized corrosion with thick porous
products, primarily composed of zinc phosphates and carbonates.
The cellular response of human bone marrow mesenchymal stem cells (hMSC) and human
vascular cells (HCECs, HASMC, HAEC) to Zn2+ was recently investigated [16,26,69,70]. According to
Zhu et al. [70], Zn biomaterial can support hMSC adhesion and proliferation and zinc ions can lead to
enhanced regulation of genes, cell survival/growth and differentiation, extracellular matrix (ECM)
mineralization, and osteogenesis. The stimulation of osteogenesis by ionic zinc has been supported by
numerous studies [71–79]. In the case of human vascular cells, Zn2+ at low concentrations can enhance
cell viability, proliferation, adhesion, spreading, migration, and F-actin and vinculin expression, while
decreasing cell adhesion strength. In contrast, high concentrations of Zn2+ elicited opposite effects.
Gene expression profiles revealed that the most affected functional genes were related to angiogenesis,
inflammation, cell adhesion, vessel tone, and platelet aggregation [26]. Since the Zn2+ concentration is
intrinsically related to the implant degradation rate, a slow corrosion rate with controlled release of
Zn2+ is desirable to maintain a low concentration profile of Zn2+ in the local tissues, in order to benefit
cellular functions [16]. A high concentration of Zn2+ may overwhelm metal divalent ion-dependent
intracellular signaling pathways, stimulate oxidative stress pathways, inducing apoptosis or necrosis,
and generally contribute to negative side effects in cell populations adjacent to the implant.
4.1.2. In Vivo Examination
Bowen et al. studied the in vivo performance of zinc wires (99.99%) over 6 months when
implanted into the abdominal aorta of adult rats [59,80]. They found uniform corrosion with
linearly increasing corrosion rates over the residence time. The corrosion rate after 1.5 months
was below the 0.02 mm/year degradable stent benchmark and increased to 0.05 mm/year (~0.4 and
~0.97 mg/day, respectively) after 6 months, both of which are far below the daily allowance of zinc
(15 mg/day) [59]. In addition, a histological examination indicated excellent biocompatibility with
the arterial tissue as well as tissue regeneration within the original footprint of the degrading implant.
Intriguingly, observations of low cellular density and a distinct lack of smooth muscle cells adjacent to
the implant interface indicates that the Zn2+ ions released from a zinc implant may suppress restenosis
pathways [80]. Yang et al. [81] investigated the degradation of pure zinc stents over one year in a rabbit
abdominal aorta model. They reported an excellent biocompatibility, without severe inflammation,
platelet aggregation, thrombosis formation or obvious intimal hyperplasia. The degradation rates were
matched to the artery healing process. Moreover, the pure zinc stent retained its mechanical integrity
for 6 months and degraded to 41.75 ± 29.72% of its original volume after 12 months of implantation.
4.2. Zinc Alloys
The biocompatibility of absorbable biomaterial components must be considered, given that all
elements of the metal alloy will eventually pass through the human body [10]. Table 3 summarizes
the pathophysiology and toxicology of zinc and the alloying elements used in current zinc alloys.
Table 4 lists the corrosion performance of different zinc alloys, including their in vitro and in vivo
corrosion rates. In Table 4, the Zn–0.5Al–0.5Mg–0.5Bi alloy exhibits the highest corrosion rate
(0.28 mm/year), which for standard implants is still far below the daily allowance of zinc (15 mg/day).
The tabulated data supports the notion that zinc release during the stent degradation process should
be considered safe to human systems, although toxicity at the local level will need to be examined on
a case-by-case basis.
In the ideal design of degradable biomaterials, elements with potential toxicological effects should
be avoided, and their use should be minimized if they cannot be excluded [10]. Since Mg, Ca, Cu, Mn
and Sr are essential for humans, these elements should be the first choices as alloying elements for
biomedical zinc alloys. Li et al. studied the in vitro and in vivo performance of Zn-1X binary alloys
Metals 2017, 7, 402 8 of 18
with the nutrient alloying elements, Mg, Ca and Sr [22]. The in vitro results for human morphologies
on the Zn–1X alloy surfaces, and generated pseudopods and extrace umbilical vein endothelial cells
ECV304 and Human osteosarcoma MG63 demonstrated healthy cell llular matrix secretions, compared
to an unhealthy morphology for cells cultured on pure Zn. When experimental Zn–1X pins were
implanted into mouse femurs, new bone formation in the absence of inflammation was observed
around the implantation site, in particular for the Zn–1Sr alloy. The corrosion rates of the Zn–1X pins
were 0.17, 0.19 and 0.22 mm/year for Zn–1Mg, Zn–1Ca and Zn–1Sr pins, respectively, which is far
below the daily allowance of zinc [22]. Even when adding higher amounts of Mg (3 wt %) to pure
zinc, to a concentration of 0.75 mg/mL (Zn: 0.49 ppm and Mg: 10.75 ppm), the Zn–3Mg alloy extract
exhibited acceptable cytotoxic effects on human osteoblasts. Results of the three main parameters of
cell–material interaction, which includes cell health, cell functionality, and inflammatory responses,
demonstrated acceptable cellular toxicity [19]. The addition of Mn to the Zn–Mg system increased
the susceptibility for galvanic micro-cell corrosion due to the higher electrode potential of Mn [50].
The Zn–xCu system exhibited a slightly increased corrosion rate with increasing Cu concentrations,
compared to pure Zn, but the increase was not significantly different among the Zn–xCu alloys. In vitro
testing demonstrated the cytocompatibilty of Zn–xCu alloys with human endothelial cells as well as
an antibacterial property when the Cu concentration was above 2 wt % [54]. The addition of 0.1–1%
Mg to the Zn–3Cu system increased the corrosion rate, as Mg was added [55].
The second choice of alloying element should be those that have been found to improve the
properties of magnesium alloys, including Li and Al. However, given the potential toxicity of Li and
Al, the addition of these two elements should be limited to low weight percent alloys. Moreover,
the degradation rate of zinc alloys containing these elements should match the tolerance or effective
dose range of these elements in the human body. Zhao et al. [25,56] investigated the effect of Li as a
zinc alloying element. They reported the overall quantities of lithium released from a zinc–lithium
implant (with 0.7 wt % of Li) at two orders of magnitude below the daily bodily consumption
allowances. The in vivo implantation of Zn–1Li demonstrated positive biocompatibility, with no
significant differences in serum zinc observed before, and 1–3 months after, implantation. According
to Bowen et al. [52], biodegradation of a Zn–Al stent, with a weight of ~50 mg and a 5 wt % Al
content—assuming bioabsorption of the entire stent in 2 years and a stable corrosion rate—would
result in a daily intake of ~0.003 mg of Al, substantially below the ~10 mg daily intake for an average
person. In their in vivo studies [20,52], Zn–Al (1, 3 and 5% Al) strips were implanted in the wall of the
abdominal aorta of adult Sprague–Dawley rats. The Zn–Al systems exhibited acceptable compatibility
with surrounding arterial tissue, as the histopathological analysis failed to identify necrotic tissue in
the samples examined, although indications of chronic and acute inflammation were both identified.
Moreover, the pattern of corrosion was modified through Al additions, with intergranular corrosion
observed in all Zn–Al alloys. Intergranular corrosion accelerates the oxidation of zinc to zinc oxide,
whose volume expansion produces implant cracking and fragmentation. The addition of 0.1–0.5 wt
% Mg to the Zn–Al system decreased the corrosion rate with increasing Mg content, after 720 h of
immersion in simulated body fluid (SBF) solution. The cytotoxicity results demonstrated acceptable
biocompatibility of the Zn–0.5Al–0.5Mg alloy, with superior antibacterial activity relative to the other
alloys [51].
Presently, the pathophysiology and toxicology of Ag and Bi remain unclear. Silver has been
used clinically for decades to treat burns and assist with wound healing, due to its antibacterial
properties, and has diverse medical applications [45,82,83]. Bi is generally considered less toxic
than other heavy metal elements, such as antimony, and purified bismuth metal has been used to
prepare a number of pharmaceutical products [53,83]. In two studies, the addition of Ag (2.5–7%)
to pure zinc matrix and the addition of Bi (0.1–0.5%) to ternary Zn–Al–Mg alloy slightly increased
the degradation rate. This is likely due to the increased galvanic coupling between the Zn and
AgZn3/Mg3Bi2 secondary phases [45,53]. In vitro cytotoxicity tests indicated a more toxic effect on
MC3T3-E1 cells for Zn–Al–Mg–Bi alloys, compared to the Zn–Al–Mg alloy [53].
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Table 3. Summary of the pathophysiology and toxicology of zinc and select alloying elements [8,10,11,83] and their effect on zinc alloys.
Element Blood SerumLevel Daily Allowance Pathophysiology Toxicology Effect on Zinc Alloys
Essential Elements
Mg 17.7–25.8 mg/L 700 mg
Activator of many enzymes; co-regulator of
protein synthesis and muscle contraction;
stabilizer of DNA and RNA
Excessive Mg leads to nausea Mg: ↑mechanical properties &↑corrosion rates [22]
Ca 36.8–39.8 mg/L 800 mg
More than 99% have structural functions in
the skeleton; the solution Ca has signaling
functions, including muscle contraction,
blood clotting, cell function, etc.
Inhibit the intestinal absorption of other essential minerals Ca: ↑mechanical properties &↑corrosion rates [22]
Fe 5000–17,600 mg/L 10–20 mg
Component of several metalloproteins;
crucial in vital biochemical activities, i.e.,
oxygen sensing and transport
Iron toxicity gives rise to lesions in the gastrointestinal tract,
shock and liver damage
Fe: ↑corrosion rates by galvanic
corrosion mechanism [15]
Essential Trace Elements
Zn 0.8–1.14 mg/L 15 mg Trace element; appears in all enzyme classes;most Zn appears in muscle
Neurotoxic and hinders bone development at higher
concentrations -
Cu 4.51–8.32 mg/L 1–3 mg
Cu plays a vital role in the immune system;
has beneficial effects on endothelial cell
proliferation and has been reported to
enhance antibacterial properties [55]
Excessive Cu (>1 mg/day) can cause neurodegenerative
diseases, including Alzheimer’s, Menkes and
Wilson’s diseases [55]
↑Cu (1–4%): ↑mechanical properties
& ↑corrosion rates [37,54]
Mn <0.0008 mg/L 4 mg
Activator of enzymes; Mn deficiency is
related to osteoporosis, diabetes mellitus,
and atherosclerosis
Excessive Mn results in neurotoxicity
Mn improves the casting process.
Mn ↑ susceptibility of galvanic
micro-cell corrosion [50]
Other Elements
Sr 0.17 mg a 2 mg
99% is located in bone; shows dose
dependent metabolic effects on bone;
low doses stimulate new bone formation
High doses induce skeletal abnormalities Sr: ↑mechanical properties &↑corrosion rates [22]
Li 0.002–0.004 mg/L 0.2–0.6 mg Used in the treatment of manicdepressive psychoses
Plasma concentrations of 2 mM are associated with reduced
kidney function and neurotoxicity, 4 mM may be fatal
Li: ↑ultimate tensile strength,
↓ductility & ↓corrosion rate [56]
Al 0.0021–0.0048mg/L - -
Primarily accumulates in the bone and nervous systems;
implicated in the pathogenesis of Alzheimer’s disease;
can cause muscle fiber damage; decreases osteoblast viability
Al: ↑mechanical properties &
↑corrosion rates
a Sr concentration in total blood [8].
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Table 4. In vitro and in vivo corrosion rates of different zinc alloys.
Alloy
In Vitro Corrosion Rate In Vivo Corrosion Rate
(mm/year)
References
Electrochemical (µA/cm2) Immersion (mm/year)
Zn
1.8–9.2 (Hank’s) 0.05 (plasma)
0.04 (whole blood)
0.035 (PBS)
0.027–0.13 (Hank’s) 0.02–0.05 (1.5–6 months) [9,20,22,23,31,32,45,53,59]
Zn * 8.98 - - [9]
Zn–Mg
Zn–0.15Mg c 11.52 (Hank’s) 0.17 (Hank’s) - [9]
Zn–0.15Mg *,c 10.98 (Hank’s) - - [9]
Zn–0.5Mg c 11.73 (Hank’s) 0.175 (Hank’s) - [9]
Zn–0.5Mg *,c 11.01 (Hank’s) - - [9]
Zn–1Mg f/ZnMg1 b
9.9–11.9 (Hank’s)
0.28–1.2 (SBF)
0.74 (PBS)
0.085–0.18 (Hank’s)
0.06–0.28 (SBF)
0.027 (PBS)
0.17 [9,22,42,46,47]
Zn–1Mg * 11.32 (Hank’s) 0.12 (SBF) - [9,46]
Zn–1.2Mg 7.7 (Hank’s) 0.08 (Hank’s) - [3]
Zn–1.2Mg * 12.4 (Hank’s) 0.11 (Hank’s) - [3]
Zn–1.5Mg d/ZnMg1.5 b 8.8 (SBF)
0.063 (Hank’s)
0.05 (SBF) - [4,36]
Zn–3Mg/ZnMg3 b
9.01 (Hank’s)
7.4 (SBF)
0.13 (Hank’s)
0.06–0.21 (SBF) - [9,42,48]
Zn–3Mg * 8.6 (Hank’s) - - [9]
Zn–3Mg *** - 0.13 (SBF) - [48]
Zn–1.5Mg–0.1Ca d - 0.12 (Hank’s) - [36]
Zn–1Mg–0.5Ca 4.3 (PBS) 0.37 (PBS) [47]
Zn—1Mg–1Ca e 0.17 (Hank’s) 0.09 (Hank’s) - [44]
Zn—1Mg–0.1Sr 7.85 (Hank’s) - - [49]
Zn–1Mg–0.5Sr 7.83 (Hank’s) - - [49]
Zn–1.5Mg–0.1Sr d - 0.1 (Hank’s) - [36]
Zn–1Mg–1Sr e 0.175 (Hank’s) 0.095 (Hank’s) - [44]
Zn–1Mg–0.1Mn 17.21 (Hank’s) 0.12 (Hank’s) - [50]
Zn–1.5Mg–0.1Mn 9.34 (Hank’s) 0.09 (Hank’s) - [50]
Zn–Ca
Zn–1Ca f 10.75 (Hank’s) 0.09 (Hank’s) 0.19 [22]
Zn–1Ca–1Sr e 0.185 (Hank’s) 0.11 (Hank’s) - [44]
Zn–Sr
Zn–1Sr f 11.76 (Hank’s) 0.095 (Hank’s) 0.22 [22]
Zn–Al
Zn–0.5Al 11.08 (Hank’s)20 (SBF)
0.14 (Hank’s)
15 (SBF) - [9,51]
Zn–0.5Al *,c 9.6 (Hank’s) - - [9]
Zn–1Al 11.11 (Hank’s) 0.16 (Hank’s) - [9]
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Table 4. Cont.
Alloy
In Vitro Corrosion Rate In Vivo Corrosion Rate
(mm/year)
References
Electrochemical (µA/cm2) Immersion (mm/year)
Zn–1Al * 9.7 (Hank’s) - - [9]
ZnAl4Cu1 b 5.2 (SBF) 0.07 (SBF) - [42]
ZA0.1Mg 17 (SBF) 0.13 (SBF) - [51]
ZA0.3Mg 11.2 (SBF) 0.11 (SBF) - [51]
ZA0.5Mg/Zn–0.5Al–0.5Mg 9.5 (SBF) 0.11–0.15 (SBF) - [51,53]
Zn–0.5Al–0.5Mg–0.1Bi 12 (SBF) 0.17 (SBF) - [53]
Zn–0.5Al–0.5Mg–0.3Bi 16 (SBF) 0.2 (SBF) - [53]
Zn–0.5Al–0.5Mg–0.5Bi 23 (SBF) 0.28 (SBF) - [53]
ZA4–1 2.986 (Hank’s) - - [31]
ZA4–3 7.209 (Hank’s) - - [31]
ZA6–1 5.331 (Hank’s) - - [31]
Zn–Cu
Zn–1Cu *,a - 0.033 (c-SBF) - [54]
Zn–2Cu *,a - 0.027 (c-SBF) - [54]
Zn–3Cu *,a 0.372 (Hank’s) 0.012 (Hank’s)0.03 (c-SBF) - [54,55]
Zn–4Cu *,a 4.1 (Hank’s) 0.009 (Hank’s)0.025 (c-SBF) - [37,54]
Zn–3Cu–0.1Mg * 1.18 (Hank’s) 0.023 (Hank’s) - [55]
Zn–3Cu–0.5Mg * 1.56 (Hank’s) 0.03 (Hank’s) - [55]
Zn–3Cu–1Mg * 12.4 (Hank’s) 0.0432 (Hank’s) - [55]
Zn–Ag
Zn–2.5Ag 9.2 (Hank’s) 0.079 (Hank’s) - [45]
Zn–5Ag 9.7 (Hank’s) 0.081 (Hank’s) - [45]
Zn–7Ag 9.9 (Hank’s) 0.084 (Hank’s) - [45]
Zn–Li
Zn–2Li 0.011 (SBF) - - [25]
Zn–4Li 0.004 (SBF) - - [25]
Zn–6Li 0.0038 (SBF) - - [25]
Zn–1Li - - 0.02–0.05 [56]
SBF: simulated body fluid; PBS: phosphate buffered saline; * Hot extrusion; *** Homogenisation; a Data gathered from figure in literature [54] (Figure 7); b Data gathered from figure in
literature [42] (Figure 5b); c Data gathered from figure in literature [9] (Figure 12); d Data gathered from figure in literature [36] (Figure 5); e Data gathered from figure in literature [44]
(Figure 7); f Data gathered from figure in literature [22] (Figure 3b).
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5. Mechanical Properties of Zinc Alloys
Implanted biomaterials, such as bone plates and stents, should be compatible with the mechanical
properties of the substituted tissue [10]. Table 5 compares the mechanical properties of zinc and current
zinc-based alloys to bone and arterial tissues. It is apparent that the mechanical properties of pure zinc
are insufficient for bone and arterial medical device applications, in particular compared to cortical
bone. The most effective way to address this issue is by adding alloying elements and/or through the
refinement of grain size by thermomechanical processing [9].
Zinc alloys exhibit a wide range of ultimate tensile strengths and elongations, from 87 to 399 MPa
and from 0.9% to ~170%, respectively. It can be seen from Table 5 that even minor alloying can
significantly improve mechanical properties; for example, adding 0.15% Mg to pure zinc improves
its ultimate tensile strength from 18 MPa to 250 MPa, and the elongation fraction from 0.32% to
22% [9,44]. Moreover, hot rolling and hot extrusion contribute to the strength and ductility of zinc
alloys [3,9,44,46]. For example: the yield strength (YS), ultimate tensile strength (UTS) and elongation
of as-cast Zn–1Mg–1Ca are 80 MPa, 130 MPa, and 1%, respectively. Meanwhile, the YS, UTS and
elongation properties of Zn-based ternary alloy samples are improved to 138 MPa, 197 MPa, and 8.5%
after hot rolling and 205 MPa, 250 MPa, and 5.2% after hot extrusion, respectively [44]. Therefore, it is
feasible to satisfy strength requirements for zinc alloys through conventional metallurgical approaches.
Table 5. Mechanical properties of bone and arterial tissues, compared with current biomedical
zinc alloys.
Tissue/Alloy
Mechanical Properties
ReferencesYield Strength
(YS) (MPa)
Ultimate
Tensile
Strength
(UTS) (MPa)
Elongation (%) Hardness (HV)
Cortical bone 104.9–114.3 35–283 5–23 - [10,11]
Cancellous bone - 1.5–38 - - [10,11]
Arterial wall - 0.5–1.72 - - [10,11]
Zn c 10 18 0.32 38 [44]
Zn *,c 35 60 3.5 - [44]
Zn **,c,d 30–110 50–140 5.8–36 39 [44,52]
Zn–Mg
Zn—0.15Mg * 114 250 22 52 [9]
Zn–0.5Mg * 159 297 13 65 [9]
Zn–1Mg/ZnMg1 180 340 6 75–86 [9,22,42,47]
Zn–1Mg *,f 175 250 12 - [46]
Zn–1.2Mg 116 130 1.4 93 [3]
Zn–1.2Mg * 220 362 21 96 [3]
Zn-1.5Mg 112 150 1.3 155 [36]
Zn–3Mg/ZnMg3 - 104 2.3 201 [48]
Zn–3Mg * 291 399 1 117 [9]
Zn–3Mg *** - 88 8.8 175 [48]
Zn–1.5Mg–0.1Ca 173 241 1.72 150 [36]
Zn–1Mg–0.5Ca - 150 1.34 116 [47]
Zn–1Mg–1Ca c 80 130 1 90 [44]
Zn–1Mg–1Ca *,c 205 250 5.2 - [44]
Zn–1Mg–1Ca **,c 138 197 8.5 105 [44]
Zn–1Mg–0.1Sr 109 133 1.4 94 [49]
Zn–1Mg–0.5Sr 129 144 1.1 109 [49]
Zn–1.5Mg–0.1Sr 130 209 2.0 145 [36]
Zn–1Mg–1Sr c 85 135 1.2 85 [44]
Zn–1Mg–1Sr *,c 200 250 7.3 - [44]
Zn–1Mg–1Sr **,c 140 200 9.7 90 [44]
Zn–1Mg–0.1Mn 114 132 98 1.11 [50]
Zn–1.5Mg–0.1Mn 115 122 149 0.77 [50]
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Tissue/Alloy
Mechanical Properties
ReferencesYield Strength
(YS) (MPa)
Ultimate
Tensile
Strength
(UTS) (MPa)
Elongation (%) Hardness (HV)
Zn–Ca
Zn–1Ca 119 165 2 73 [22]
Zn–1Ca–1Sr c 83 140 1.1 90 [44]
Zn–1Ca–1Sr *,c 210 260 6.8 - [44]
Zn–1Ca–1Sr **,c 145 203 8.6 85 [44]
Zn–Sr
Zn–1Sr 120 171 2 61 [22]
Zn–Al
Zn–0.5Al * 119 203 33 59 [9]
Zn–1Al * 134 223 24 73 [9]
Zn–1Al **,d 190 220 24 - [52]
Zn–3Al **,d 200 240 30 - [52]
Zn–5Al **,d 240 300 16 - [52]
ZnAl4Cu1 171 210 1 80 [42]
ZA0.1Mg - 87 1.6 79 [51]
ZA0.3Mg - 93 1.7 89 [51]
ZA0.5Mg/Zn–0.5Al–0.5Mg - 92–102 1.73–2.1 94 [51,53]
Zn–0.5Al–0.5Mg–0.1Bi - 102 2.4 102 [53]
Zn–0.5Al–0.5Mg–0.3Bi - 108 2.7 109 [53]
Zn–0.5Al–0.5Mg–0.5Bi - 98 1.97 99 [53]
ZA4–1 75 180 ~112 50 [31]
ZA4–3 110 200 ~130 55 [31]
ZA6–1 175 275 ~170 65 [31]
Zn–Cu
Zn–1Cu * 149 186 21 - [54]
Zn–2Cu * 199 240 46 - [54]
Zn–3Cu * 213 257 47 - [54,55]
Zn–4Cu * 227–250 270 51 - [37,54]
Zn–3Cu–0.1Mg *,b 340 355 5 - [55]
Zn–3Cu–0.5Mg *,b 390 400 2 - [55]
Zn–3Cu–1Mg *,b 427 441 0.9 - [55]
Zn–Ag
Zn–2.5Ag *,a 174 200 35 - [45]
Zn–5Ag *,a 236 250 36 - [45]
Zn–7Ag *,a 258 287 32 - [45]
Zn–Li
Zn–2Li **,e 240 360 14.2 98 [25]
Zn–4Li **,e 420 440 13.7 115 [25]
Zn–6Li **,e 470 560 2.2 136 [25]
Zn–1Li 238 274 17 97 [56]
* Hot extrusion; ** Hot rolling; *** Homogenisation; a Data gathered from figure in literature [45]; (Figure 8a); b Data
gathered from figure in literature [55] (Figure 5b); c Data gathered from figure in literature [44] (Figures 3 and 4);
d Data gathered from figure in literature [52] (Figure 7); e Data gathered from figure in literature [25] (Figure 7);
f Data gathered from figure in literature [46] (Figure 8).
6. Concluding Remarks and Perspectives
The previous several years have seen rapid growth in the research and development of zinc-based
medical devices, due to their biological and biodegradability properties that match the human body.
Zn is one of the most abundant essential elements in the human body, playing essential roles in human
health. Moreover, zinc overcomes the limitations inherent to iron and magnesium, both pure and
alloyed. This includes more suitable corrosion rates as well as easier casting and processing. In this
review, current research progress for zinc and zinc-based alloys has been presented and discussed.
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In the case of pure zinc, in vivo studies have demonstrated a great potential for use as biodegradable
stents. The degradation of pure zinc stents proceeded with excellent biocompatibility to local cells and
tissue and was aligned with the time course of arterial healing. Although the pure zinc stent poorly
retained its mechanical integrity during the healing phase, this can be overcome by using zinc alloys
with superior strength.
Despite the advantages, the use of pure Zn as a biodegradable metal is limited due to its
insufficient strength, plasticity and hardness for most medical applications. Adding alloying elements
and refining grain sizes via thermomechanical processing are commonly applied to modify the
mechanical properties of metallic materials. A number of zinc alloys have been developed with
nontoxic and biocompatible alloying elements that have achieved suitable mechanical properties to
serve as structure support for arteries or bone, with promising preliminary results in cell culture and
small animal models. For instance, Zn–Mg and Zn–Al at alloying concentrations of less than one
percent, have enhanced mechanical properties and achieved adequate strength and ductility, without
using excessive quantities of potentially toxic alloying elements. The mechanical properties of these
materials are generally enhanced considerably from the as-cast state, following extrusion to break
up embrittling intermetallics and to refine the grain size. Because each biomedical device (e.g., stent,
bone plate or screw, etc.) requires unique processing conditions that can dramatically change material
properties, it is crucial to evaluate candidate materials through these processing steps.
Looking ahead, researchers are required to translate the wealth of biomedical research data into
an understanding of how these materials will behave within test subjects. Hence, it will be important
to clarify the molecular mechanisms that stimulate beneficial cellular remodeling activities in response
to Zn2+ and the alloying element ions. Next generation zinc implants will need to have tailored
corrosion rates in order to optimize favorable cellular responses and minimize toxicity and negative
inflammatory reactions, specific to the host tissue.
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